Neurogene (NGNE) Preferred Dividend Payments (2013 - 2014)
Neurogene's (NGNE) quarterly Preferred Dividend Payments came in at $6650.0 in Q2 2014, down 84.22% YoY from $42130.0 in Q2 2013, and down 65.98% on a QoQ basis from $19550.0 in Q1 2014.
Powered by 
Analysis
Neurogene (NGNE) Preferred Dividend Payments (2013 - 2014) Analysis & Trends
Neurogene (NGNE) has 2 years of Preferred Dividend Payments data on file, last reported at $6650.0 in Q2 2014.
- Quarterly Preferred Dividend Payments fell 84.22% year-over-year to $6650.0 in Q2 2014, while the trailing twelve-month figure through Jun 2014 was $112637.0 (changed N/A YoY) and the FY2013 annual result came in at $123074.0, down 27.05% from the prior year.
- Preferred Dividend Payments fell to $6650.0 in Q2 2014, from $19550.0 in the prior quarter.
- In the past five years, Preferred Dividend Payments ranged from a high of $44307.0 in Q1 2013 to a low of $6650.0 in Q2 2014.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Pref Dividends (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Neurogene | 864.53 Mn | 864.53 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2014 | 1.00 |
| Mar 12, 2014 | 19,550.00 |
| Jun 30, 2013 | 42,130.00 |
| Mar 31, 2013 | 44,307.00 |